Dr. Silvina del Carmen earned her undergraduate degree in Biotechnology and her doctoral degree in Biochemistry from the National University of Tucuman in Argentina. Under the supervision of Drs. Jean Guy LeBlanc and Alejandra de Moreno, she studied the anti-inflammatory activity of genetically modified lactic acid bacteria and their potential use as a complementary probiotic therapy for inflammatory bowel diseases. During her Ph.D training, she naturally developed an interest in the regulation of the host innate immune response, and thus pursued further postdoctoral training in Dr. Rothlin’s lab at Yale University, where she studied the role of molecules that regulate clotting and inflammation; and in Dr. Jacques Banchereau’s lab at The Jackson Laboratory for Genomic Medicine, where she performed big data analysis for the discovery of novel splice isoforms on clinical samples of Lupus patients.

Dr. Jain brings extensive microbiology experience to Artizan. Prior to joining Artizan, she led the microbiology department at Vanessa Research in a Hamden based company. She was instrumental in initiating an engineered phage therapy project for Cholera treatment and participated in pre-clinical research and formulation of their lead candidate, Shylicine, treatment for a rare intestinal disorder. Dr. Jain spent almost 10 years at Yale University for her postdoctoral work and focused on the molecular mechanisms for assembly of surface associated virulence factors in aerobic and anaerobic Gram-negative bacteria. In addition, she was the lead researcher in a pediatric cystic fibrosis microbiome study. Dr. Jain earned her doctorate degree from Jawaharlal Nehru University in India.

Ms. Mucha brings 25 years of executive administration experience to the Artizan team. Most recently, she worked at Alexion Pharmaceutical in the Global Business Development and Strategy Department. Additionally, Ms. Mucha spent more than 20 years in financial services at various Fortune 500 companies where she managed complex events and helped onboard and staff growing businesses. She received her B.A. in Business Administration from American InterContinental University.

Mr. John brings his prior experience in the agricultural biotech industry to the Artizan team. Prior to joining the company, he worked as a microbiology research associate at Native Microbials, where he developed live microbial supplements for livestock and companion animals. As a member of the microbial discovery team at Bayer Crop Science, Mr. John helped develop microbial products intended to improve crop efficacy. He received his B.S. in Animal Biology from the University of California, Davis.

Prior to joining Artizan, Ms. Cooney-Walsh worked at Bristol-Myers Squibb for 13 years as a veterinary scientist where she performed lab animal research and discovered a passion for the animals that lead to many important scientific discoveries. She began her career working in a zoo and a small animal veterinary practice. She received her B.S. in Zoology from Washington State University and holds a certificate as a Laboratory Animal Technologist with the American Association for Laboratory Animal Science.

Ms. Chintha brings more than 10 years of industrial experience to Artizan in the fields of microbiome, virology, immunology, molecular biology and biochemistry including target validation through progressing lead candidates into clinical trials. Prior to joining Artizan, she worked as a Senior R&D Specialist in the Infectious Diseases department at Regeneron Pharmaceuticals. Ms. Chintha received her M.S. in Biological Sciences from University of Massachusetts and her B.S. in Biotechnology from Jawaharlal Nehru Technological University.

Mr. Robinson has nearly 30 years of pharmaceutical research experience. He joined Artizan after spending a decade working to develop oncology therapeutics at two New Haven-based biotechnology companies, Kolltan and Cybrexa. He began his career studying yeast replication at the UConn Health Center and transitioned to developing small molecule and biological therapeutics targeting HIV and hepatitis C virus at Bristol-Myers Squibb and osteoporosis and diabetes at Pfizer. Mr. Robinson received his B.S. in Microbiology from the University of Connecticut.

Ms. Ledoux has more than a decade of experience in lab management and operations in both academia and biotech, building safety programs, procurement systems and using technology to streamline laboratory operations. Prior to Artizan, she served as Laboratory Manager for Assembly Biosciences, supporting the cGMP microbiome CMC group with Phase 1 clinical supply development, manufacture and release. Ms. Ledoux is in the process of completing her Project Management Professional certification to support the therapeutic development programs as they mature. She received her B.S. in Biology from Massachusetts College of Liberal Arts.

Dr. Hoekstra has worked in pharmaceutical R&D as a medicinal chemist and intellectual property coordinator for more than 30 years. Prior to joining Artizan, he served as Senior Vice President of Medicinal Chemistry at Viamet Pharmaceuticals Inc., where he co-invented the Phase 3 antifungal oteseconazole and the Phase 2B anticancer agent seviteronel. Prior to working with Viamet, Dr. Hoekstra held the position of Associate Director in Discovery Medicinal Chemistry at GlaxoSmithKline where he coordinated the introduction of a group of nuclear receptor modulator programs into the portfolio. In the 1990s, he directed the discovery and lead optimization of several clinical new chemical entities such as the Phase 2B antithrombotic elarofiban in Johnson & Johnson’s Department of Drug Discovery. Dr. Hoekstra has co-authored over 100 publications, holds 75 issued U.S. patents and has presented several invited lectures. He received his B.S. in Chemistry from Hope College, Holland, MI and subsequently earned his Ph.D. in Organic Chemistry from Emory University, Atlanta, GA.

Dr. Schofield’s academic career focused on the molecular mechanisms that enable bacteria to propagate and thrive in the mammalian host. He completed his doctoral work in the laboratory of Christine Jacobs-Wagner, where he studied bacterial chromosome segregation by developing novel image analysis software. His post-doctoral work was done with Andrew Goodman at Yale University, where he utilized transcriptomics, metabolomics and epistasis analysis to elucidate how human gut bacteria adjust central carbon metabolism to the mammalian digestive tract.